Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Assets (2016 - 2025)

Assembly Biosciences has reported Non-Current Assets over the past 11 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $3.0 million for Q4 2025, down 17.03% from a year ago — trailing twelve months through Dec 2025 was $13.0 million (up 20.4% YoY), and the annual figure for FY2025 was $3.0 million, down 17.03%.
  • Non-Current Assets for Q4 2025 was $3.0 million at Assembly Biosciences, down from $3.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ASMB hit a ceiling of $60.8 million in Q3 2021 and a floor of $2.0 million in Q3 2023.
  • Median Non-Current Assets over the past 5 years was $3.4 million (2023), compared with a mean of $15.4 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 89.45% in 2023 and later skyrocketed 55.44% in 2025.
  • Assembly Biosciences' Non-Current Assets stood at $36.9 million in 2021, then plummeted by 86.9% to $4.8 million in 2022, then tumbled by 37.1% to $3.0 million in 2023, then rose by 20.72% to $3.7 million in 2024, then decreased by 17.03% to $3.0 million in 2025.
  • The last three reported values for Non-Current Assets were $3.0 million (Q4 2025), $3.2 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.